Eptinezumab + Placebo

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Episodic Migraine

Conditions

Episodic Migraine

Trial Timeline

Jun 8, 2023 → Aug 31, 2027

NCT ID

NCT05897320

About Eptinezumab + Placebo

Eptinezumab + Placebo is a phase 3 stage product being developed by Lundbeck for Episodic Migraine. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05897320. Target conditions include Episodic Migraine.

What happened to similar drugs?

3 of 15 similar drugs in Episodic Migraine were approved

Approved (3) Terminated (1) Active (11)

✅Atogepant + UbrogepantAbbVieApproved

✅AMG334 + Oral ProphylacticNovartisApproved

✅MethylprednisoloneBrain BiotechApproved

🔄DFN-11Dr. Reddy's LaboratoriesPhase 3

🔄GalcanezumabEli LillyPhase 3

🔄Galcanezumab + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05897320	Phase 3	Recruiting	Jun 8, 2023	Aug 31, 2027	Episodic Migraine
NCT05452239	Approved	Completed	Jul 1, 2022	Mar 13, 2025	Migraine
NCT04965675	Phase 3	Recruiting	Jun 30, 2021	Oct 31, 2026	Chronic Migraine in Children
NCT04688775	Phase 3	Completed	Dec 23, 2020	Oct 5, 2023	Cluster Headache, Episodic
NCT04418765	Phase 3	Completed	Jun 1, 2020	Sep 15, 2022	Migraine
NCT04336449	Phase 1	Completed	Apr 1, 2020	Aug 13, 2020	Healthy
NCT04152083	Phase 3	Completed	Nov 7, 2019	Jul 8, 2020	Migraine

Competing Products

19 competing products in Episodic Migraine

See all competitors

Product	Company	Stage	Hype Score
DFN-11	Dr. Reddy's Laboratories	Phase 3	37
Galcanezumab	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 3	44
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	32
Atogepant 60 mg	AbbVie	Phase 3	40
Atogepant + Ubrogepant	AbbVie	Approved	43
Atogepant + Placebo-Matching Atogepant	AbbVie	Phase 3	47
SOM230 + Placebo	Novartis	Phase 2	27
AMG334 + Oral Prophylactic	Novartis	Approved	43
AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS)	Novartis	Phase 3	40
Erenumab	Novartis	Phase 3	40
Placebo + AMG 301	Amgen	Phase 2	35
Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)	Pfizer	Phase 1	29
Eptinezumab + Placebo	Lundbeck	Phase 3	37
Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A	Ipsen	Phase 3	41
IPN10200 + IPN10200 dose A + IPN10200 dose B	Ipsen	Phase 2	39
Methylprednisolone	Brain Biotech	Approved	33